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Shielding of a Lipooligosaccharide IgM Epitope Allows Evasion of
Neutrophil-Mediated Killing of an Invasive Strain of Nontypeable
Haemophilus influenzae
Jeroen D. Langereis, Jeffrey N. Weiser
Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
ABSTRACT Nontypeable Haemophilus influenzae is a frequent cause of noninvasive mucosal inflammatory diseases but may also
cause invasive diseases, such as sepsis andmeningitis, especially in children and the elderly. Infection by nontypeableHaemophi-
lus influenzae is characterized by recruitment of neutrophilic granulocytes. Despite the presence of a large number of neutro-
phils, infections with nontypeable Haemophilus influenzae are often not cleared effectively by the antimicrobial activity of these
immune cells. Herein, we examined how nontypeable Haemophilus influenzae evades neutrophil-mediated killing. Transposon
sequencing (Tn-seq) was used on an isolate resistant to neutrophil-mediated killing to identify genes required for its survival in
the presence of human neutrophils and serum, which provided a source of complement and antibodies. Results show that non-
typeable Haemophilus influenzae prevents complement-dependent neutrophil-mediated killing by expression of surface
galactose-containing oligosaccharide structures. These outer-core structures block recognition of an inner-core lipooligosaccha-
ride epitope containing glucose attached to heptose HepIII-1,2-Glc by replacement with galactose attached to HepIII or
through shielding HepIII-1,2-Glc by phase-variable attachment of oligosaccharide chain extensions. When the HepIII-1,2-
Glc-containing epitope is expressed and exposed, nontypeable Haemophilus influenzae is opsonized by naturally acquired IgM
generally present in human serum and subsequently phagocytosed and killed by human neutrophils. Clinical nontypeableHae-
mophilus influenzae isolates containing galactose attached to HepIII that are not recognized by this IgM are more often found to
cause invasive infections.
IMPORTANCE Neutrophils are white blood cells that specialize in killing pathogens and are recruited to sites of inflammation.
However, despite the presence of large numbers of neutrophils in the middle ear cavity and lungs of patients with otitis media or
chronic obstructive pulmonary disease, respectively, the bacterium nontypeable Haemophilus influenzae is often not effectively
cleared from these locations by these immune cells. In order to understand how nontypeable Haemophilus influenzae is able to
cause inflammatory diseases in the presence of neutrophils, we determined the mechanism that underlies resistance to
neutrophil-mediated killing. We have shown that nontypeable Haemophilus influenzae prevents binding of antibodies of the
IgM subtype through changes in their surface lipooligosaccharide structure, thereby preventing complement activation and
clearance by human neutrophils.
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Invasive disease caused byHaemophilus influenzae has decreaseddramatically with the introductions of the H. influenzae type B
conjugate vaccine (1). Currently, nontypeable H. influenzae
(NTHi) is themost commonly isolated formofH. influenzae caus-
ing invasive infections in Europe (2). This group of H. influenzae
strains lacks a capsule, which renders them more sensitive to an-
tibacterial actions of the innate immune system. As such, NTHi is
often found as a cause of mucosal inflammatory diseases, includ-
ing otitis media (OM) (3), sinusitis (4), and exacerbations in pa-
tients with chronic obstructive pulmonary disease (COPD) (5).
However, NTHi can also cause more invasive diseases, such as
sepsis andmeningitis (6). In all these situations, NTHi encounters
the antimicrobial activity of the host’s immune system and there-
fore has developed mechanisms to survive and multiply during
infection.
The immune response to NTHi includes secretion of cytokines
and chemokines by the respiratory epithelium and resident im-
mune cells, which attracts various types of nonresident immune
cells, including large numbers of neutrophils, to the site of inflam-
mation (7). Neutrophils possess multiple antimicrobial activities
contributing to the clearance of bacterial pathogens, including the
generation of reactive oxygen species (ROS), release of antimicro-
bial peptides and proteases from their granules, formation of ex-
tracellular traps (neutrophil extracellular traps [NETs]), and po-
tent phagocytic capacity (8). Even though neutrophils are
specialized killers, these cells are often not able to clear NTHi
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infections. Neutrophil recruitment has even been shown to be an
advantage for NTHi survival by eliminating sensitive competitors
like Streptococcus pneumoniae (9). In addition, NTHi actively in-
ducesNET formation in vitro, whichmay promote its survival (10,
11).
Bacteria need to be opsonized by antibodies and/or comple-
ment factors, such as C3b and C5b, to be efficiently phagocytosed
by neutrophils (12). Unencapsulated bacteria, like NTHi, are par-
ticularly susceptible to complement-mediated killing and subse-
quent phagocytosis by neutrophils due to the lack of a protective
surface structure. In response to this threat, NTHi has developed
multiple strategies to evade the bactericidal activity of the human
complement system. For instance, NTHi binds the complement
control proteins C4b binding protein (C4BP) and factor H (13,
14). In addition, variation and modifications in its lipooligosac-
charide (LOS) composition have been shown to prevent comple-
ment activation (15–18). The LOS structure of NTHi consists of
three parts: (i) lipid A, (ii) an inner core comprised of a single
3-deoxy-D-manno-octulosonic acid (Kdo) linked to three con-
served heptoses (Hep), and (iii) an outer core containing variable
oligosaccharide extensions (19). Specific LOS structures have
been shown to prevent binding of antibody and complement fac-
tor C4b, which increases their resistance to complement-
mediated lysis (15, 16). In addition,NTHi prevents recognition by
antibodies through incorporation of phosphorylcholine (PCho)
and other “self-antigens” into the LOS structure (17, 18). How-
ever, mechanisms that prevent neutrophil-mediated killing are
incompletely understood.
We used transposon sequencing (Tn-seq) technology to iden-
tify genes required for NTHi to survive in the presence of human
neutrophils. We identified an important role for phase-variable
incorporation of oligosaccharides into the LOS outer core, shield-
ing an epitope that is recognized by naturally acquired IgM,
thereby preventing complement activation, opsonization, and
killing by human neutrophils.
RESULTS
Identification of genes important for survival in the presence of
human neutrophils. To identify genes that were important for
resistance to neutrophil-mediated killing, we used Tn-seq to com-
pare survival of transposonmutants of the invasive clinical isolate
R2866. Mutants were screened in the presence of 10% pooled
normal human serum (NHS) containing opsonizing antibodies
and active complement only as a control and NHS in the presence
of freshly isolated human neutrophils from peripheral blood as a
challenge condition (see Fig. S1A in the supplemental material).
Viable counts of the mutant library exposed to NHS or NHS with
neutrophils did not differ at the start of the experiment, after 2 h of
incubation, or after the 3 h of growth in sBHI (brain heart infusion
[BHI] broth [Becton, Dickinson] supplemented with 2% Fildes
enrichment [Thermo Scientific] and 2 g/ml -NAD [Sigma-
Aldrich]) needed to obtain sufficient DNA for genomic DNA iso-
lation (see Fig. S1B).
Tn-seq analysis identified a total of 20,759 TA insertion sites
with at least 10 reads for the control condition. These insertion
sites included 17,507 insertions into 1,498 out of the 1,876 pre-
dicted genes in the R2866 genome. Among others, we found that
transposon insertions in multiple genes known to be involved in
lipooligosaccharide (LOS) biosynthesis conferred a significant de-
crease in survival in the presence of neutrophils (Table 1), with the
largest effects seen for a strain carrying transposon mutations in
the galE gene, encoding a UDP-galactose 4-epimerase needed for
reversible conversion of UDP-glucose to UDP-galactose (20).
Neutrophil-mediated killing of R2866lic1/galE is depen-
dent on phagocytosis and serine-protease activity. To study the
effects of the galE gene on resistance to neutrophil-mediated kill-
ing, we replaced the entire galE gene with a spectinomycin resis-
tance cassette. In preliminary experiments, we observed increased
neutrophil-mediated killing of the R2866galE mutant (data not
shown) but also selection for phase variants incorporating PCho
into the LOS of the R2866galE mutant, as determined by
TEPC-15 binding assessed by flow cytometry (see Fig. S2A in the
supplemental material). PCho is known to bind C-reactive pro-
tein and germline-encoded IgM (21, 22) andmodulates resistance
to complement through decreased binding of IgG (17). Therefore,
we inactivated PCho incorporation by deletion of either lic1A or
lic1D (further referred to as lic1 mutants) to evaluate the effect of
galE or other gene deletions on resistance to neutrophil-mediated
killing in the absence of this structure. Growth of R2866lic1 and
R2866lic1/galE in sBHI were not significantly different (see
Fig. S2B).
Neutrophil-mediated killing of R2866lic1/galE in 5% NHS
was dose dependent, with an NTHi/neutrophil ratio of 1:100, re-
sulting in ~80% killing (Fig. 1A), which was used in all the follow-
ing experiments. Neutrophil-mediated killing was completely de-
pendent on the presence of active complement, since neutrophils
TABLE 1 R2866 mutant library challenged with or without neutrophils with active complement for 2 ha
Total no. of
pseudoreads,
NHS
Total no. of
pseudoreads,
NHS
neutrophils
Fold
change
Adjusted
P value Gene locus
Gene
name Product
379 5 71.7 3.3E17 R2866_0222 galE UDP-glucose 4-epimerase
260 6 41.0 1.1E09 R2866_1061 rfaE Fused heptose 7-phosphate kinase/heptose 1-
phosphate adenyltransferase
113 4 26.4 2.2E06 R2866_1286 rfaD ADP-L-glycero-D-manno-heptose-6-epimerase
125 5 23.6 1.0E06 R2866_1295 rfaF ADP-heptose-LOS heptosyltransferase II
293 13 21.7 3.6E14 R2866_0033 lic2A Lipooligosaccharide biosynthesis protein Lic2A
359 37 9.5 2.9E08 R2866_1581 galU Glucose-1-phosphate uridylyltransferase
168 21 7.8 1.9E04 R2866_0055 waaQ ADP-heptose-LPS heptosyltransferase III
1,056 193 5.5 5.1E06 R2866_0326 lgtC 1,4-Alpha-galactosyltransferase (LgtC)
a Genes related to LOS biosynthesis with a5-fold decrease in total pseudoreads for NHS plus neutrophils compared to pseudoreads for NHS, P 0.05, were selected.
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with heat-inactivated NHS were not able to kill R2866lic1 or
R2866lic1/galE (Fig. 1B).
Next, we determined by which mechanisms R2866lic1/galE
was killed by human neutrophils. Cytochalasin D and protease
inhibitor (PI) cocktail showed complete inhibition of neutrophil-
mediated killing of R2866lic1/galE (Fig. 1C). Of note, we were
not able to determine the contribution of reactive oxygen species
(ROS) in neutrophil-mediated killing, since diphenylene iodo-
nium (DPI) affected survival of NTHi at concentrations needed to
inhibit ROS production by neutrophils (data not shown). We
used specific inhibitors to elucidate which type of protease was
responsible for neutrophil-mediated killing of NTHi. Whereas
myeloperoxidase (MPO) inhibitor and the cysteine protease in-
hibitor E-64 showed no effect on bactericidal activity of neutro-
phils, the serine protease inhibitors 4-(2-aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF) and
diisopropylfluorophosphate (DFP) showed complete inhibition
of neutrophil-mediated killing of R2866lic1/galE (Fig. 1D).
Therefore, we conclude that neutrophil-mediated killing of
R2866lic1/galE is dependent on phagocytosis that involves
complement-dependent uptake of the bacteria and activity of ser-
ine proteases.
The R2866lic1/galE mutant shows increased IgM and C3
binding. Since neutrophil-mediated killing of the R2866lic1/
galE mutant was dependent on phagocytosis, we compared IgG,
IgM, and C3 deposition on the bacterial surface of R2866lic1and
R2866lic1/galE by flow cytometry. Whereas binding of IgG was
not different (Fig. 2A), amarked increase in IgMbinding (Fig. 2B)
and C3 deposition (Fig. 2C) was found on the surface of the
R2866lic1/galEmutant compared to findings for the R2866lic1
control. Binding of IgMwas needed for neutrophil-mediated kill-
ing of the R2866lic1/galE mutant, since depletion of IgM (see
Fig. 2C in the supplemental material) abrogated neutrophil-
mediated killing completely (Fig. 2D). Significant increased IgM
binding was observed not only with pooled NHS but also when
donor specific NHS (Fig. 2E) or human nasal airway surface fluid
(Fig. 2F) was used.
Serum IgM can be divided into germ line-encoded IgM and
naturally acquired IgM synthesized after immune stimulation
(21). IgM is not able to pass the placental barrier; therefore, IgM
present in cord blood plasma is exclusively germ line encoded. No
difference in IgMbinding (Fig. 2G) or IgGbinding (see Fig. S2D in
the supplemental material) between R2866lic1 and R2866lic1/
galE was observed with cord blood plasma. Altogether, we con-
clude that IgM that recognizes an epitope(s) on the R2866lic1/
galEmutant was acquired fromprevious exposure and is generally
present in human serum.
IgM binds to HepIII-1,2-Glc in the R2866lic1/galE LOS
structure.Next, we set out to identify the specific LOS epitope(s)
FIG 1 Neutrophil-mediated killing of R2866lic1/galE is dependent on
phagocytosis and serine protease activity. R2866lic1 and R2866lic1/galE
were incubated with 5% pooled normal human serum (NHS) (A) or 5% heat-
inactivated (HI)-NHS (B) with or without neutrophils at different target-to-
effector ratios, and survival was determined after incubation at 37°C for
30min. (C and D) Neutrophils were preincubated with 20Mcytochalasin D
(CytoD) or 1 protease inhibitor (PI) cocktail (C) or with 1 mMMPO inhib-
itor, 10 M E-64, 500 M AEBSF, or 200 M DFP (D) for 15 min at 37°C.
R2866lic1/galE was incubated with 5% NHS with or without neutrophils,
and survival was determined after incubation at 37°C for 30 min. Statistical
significance was determined using an unpaired Student t test (B) or one-way
analysis of variance and the Tukey post hoc test (A and C to D). NS, not
significant; *, P 0.05; **, P 0.01.
FIG 2 Increased IgM and C3 binding to the bacterial surfaces of R2866lic1/
galE. R2866lic1 and R2866lic1/galE were incubated for 15 min with 5%
NHS at 37°C, and binding of human IgG (A), IgM (B), or complement factor
C3 (C) to the bacterial surface was determined by flow cytometry. (D)
R2866lic1/galEwas incubated for 15 min with 5%NHS or 5% IgM-depleted
serum at 37°C, and binding of human IgM to the bacterial surface was deter-
mined by flow cytometry. R2866lic1 andR2866lic1/galEwere incubated for
15min with 5%NHS from individual donors (E), human nasal airway surface
fluid (F), or 10% cord blood plasma at 37°C (G), and binding of IgM to the
bacterial surfacewas determined by flow cytometry. Statistical significancewas
determinedusing anunpaired student t test.NS, not significant; *,P 0.05; **,
P 0.01; ***, P 0.001.
LOS Structure Prevents Neutrophil Phagocytosis
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on the R2866lic1/galEmutant that is recognized by IgM present
in human serum. The predicted LOS structure of R2866 has oli-
gosaccharide chains extending from both HepI and HepIII and
the presence of a HepIV containing additional oligosaccharides
(Fig. 3A) (23; Elke Schweda, personal communication).
Altered oligosaccharide chain lengths of HepI, HepIII, and
HepIV for the R2866lic1/lgtC and R2866lic1/lic2A mutants or
complete deletion of oligosaccharide chains on HepI (which in-
cludes HepIV) or HepIII for the R2866lic1/lgtF and R2866lic1/
lpsA mutants, respectively, did not increase binding of IgM
(Fig. 3B) or IgG (see Fig. S2E in the supplemental material) sig-
nificantly, as determined by flow cytometry. However, deletion of
the oligosaccharide chain ofHepI in combinationwith truncation
of oligosaccharide chain length onHepIII for the R2866lic1/lgtF/
lic2A mutant increased IgM binding significantly (Fig. 3B). The
presence of glucose (Glc) attached to HepIII in a 1,2 linkage was
needed for recognition by IgM, because the R2866lgtF/lpsAmu-
tant lacking any oligosaccharide chains on HepI and HepIII
showed a significant decrease in IgM binding compared to the
R2866lic1/lgtF/lic2A mutant (Fig. 3B). In accordance with the
findings for R2866lic1/galE, an increase in IgM binding to the
R2866lic1/lgtF/lic2A mutant but not the other LOS mutants in-
creased neutrophil-mediated killing significantly (Fig. 3C).
Increased binding of IgM to the bacterial surface of the
R2866lic1/lgtF/lic2A mutant was due to an altered LOS struc-
ture, because marked binding of IgM to the LOS of the
R2866lic1/lgtFilic2A mutant was detected, whereas binding of
IgM was nearly undetectable for the R2866lic1 mutant and in-
creased slightly for the R2866lic1/lic2A mutant (Fig. 3D). From
these data, we conclude that IgM binds an epitope that contains
HepIII-1,2-Glc on the R2866lic1/lgtF/lic2A mutant.
To determine whether IgM recognized a similar epitope in the
LOS of the R2866lic1/galE and R2866lic1/lgtF/lic2A mutants,
we preincubated NHS with LOS from the R2866lic1/galE,
R2866lic1/lgtF/lic2A, or R2866lpsA/lgtFmutant as a control, to
compete with IgM binding to the bacterial surface of the
R2866lic1/lgtF/lic2A mutant. Preincubation of NHS with LOS
from the R2866lpsA/lgtF mutant did not decrease IgM binding
to the R2866lic1/lgtF/lic2A mutant. However, addition of LOS
from either R2866lic1/lgtF/lic2A or R2866lic1/galE decreased
IgM binding to the R2866lic1/lgtF/lic2A mutant in a dose-
dependent manner (Fig. 3E), which confirmed that IgM from hu-
man serumbound a similar epitope on the LOSof theR2866lic1/
galE and R2866lic1/lgtF/lic2A mutants. From these data, we
conclude that human serum contains naturally acquired IgM rec-
ognizing an epitope that includes HepIII-1,2-Glc and that an
oligosaccharide chain extension onHepIII-1,2-Glc, as well as on
oligosaccharides onHepI andHepIV, block binding of IgM to the
R2866lic1 control strain.
Phase-variable incorporation of galactose on HepIII-1,2-
Glc prevents neutrophil-mediated killing. The glucose linked to
HepIII can be substituted with galactose (Gal) by the phase-
variable gene lic2A (24, 25) (Fig. 4A). While we conducted exper-
iments with strain Rd, we observed increased IgM binding
(Fig. 4B) and neutrophil-mediated killing (Fig. 4C) for both
Rdlic1/lgtF and Rdlic1/lgtF/lic2A, whereas binding of IgG was
similar (see Fig. S2F in the supplemental material). The lack of
difference for IgM binding and neutrophil-mediated killing be-
tween Rdlic1/lgtF and Rdlic1/lgtF/lic2A would suggest that
lic2A was “phase off” in strain Rdlic1/lgtF, which we confirmed
by sequencing (see Fig. S3). Accordingly, we observed that se-
quential exposure (3 rounds) of Rdlic1/lgtF to NHS and neutro-
phils selected for Rdlic1/lgtF with lic2A “phase on” (a shift from
23 to 22 tandem repeats of CAAT within the lic2A gene) (see
Fig. S3). Phase variation of lic2A coincided with an increased LOS
size (Fig. 4D), decreased IgM binding (Fig. 4E), and increased
resistance to neutrophil-mediated killing (Fig. 4F), whereas no
difference in IgG binding was observed (see Fig. S2G). We con-
firmed that lic2A phase-on selection was essential for decreased
IgM binding and neutrophil-mediated killing because Rdlic1/
lgtF/lic2A remained sensitive to neutrophil-mediated killing after
serial treatment with NHS and neutrophils (3 rounds) (Fig. 4G).
Therefore, these data show that phase-variable incorporation of
FIG 3 Binding of IgM to HepIII-1,2-Glc increases neutrophil-mediated
killing. (A) Predicted LOS structure of NTHi strain R2866 (23; Elke Schweda,
personal communication) with phase-variable LOS synthesis genes in gray.
(B) R2866 LOSmutants were incubated for 15min with 5%NHS at 37°C, and
binding of IgM to the bacterial surface was determined by flow cytometry. (C)
R2866LOS mutants were incubated with 3% NHS with or without neutro-
phils, and survival was determined after incubation at 37°C for 30 min. (D)
LOS was isolated from R2866 LOS mutants, separated by Tris Tricine SDS-
PAGE, and visualized by silver staining, or IgM binding was detected byWest-
ern blot analysis. (E) R2866lic1/lgtF/lic2Awas incubated for 15 min with 5%
NHS that was preincubated with LOS isolated from R2866lic1/lgtF/lic2A,
R2866lic1/galE, or R2866lpsA/lgtF for 15 min at 37°C, and binding of IgM
to the bacterial surface was determined by flow cytometry. Statistical signifi-
cance was determined with a one-way analysis of variance and the Tukey post
hoc test (B and C) or two-way analysis of variance and the Bonferroni post hoc
test (E). **, P 0.01; ***, P 0.001.
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galactose ontoHepIII-1,2-Glc by Lic2A prevents binding of IgM
and increases resistance to neutrophil-mediated killing.
Binding of IgM to HepIII-1,2-Glc but not HepIII-1,2-Gal
contributes to neutrophil-mediated killing ofNTHi. Incorpora-
tion of glucose ontoHepIII is dependent on the lpsA gene. Besides
incorporation of glucose onto HepIII, LpsA can also incorporate
galactose, which is strain specific and determined by a single
amino acid difference at position 151 (26) (see Fig. S4A in the
supplemental material). In order to determine the specificity for
IgM binding for either a glucose or galactose attached to HepIII,
we constructed an Rdlic1/lgtF/lic2A strain that has a HepIII-
1,2-Glc epitope (25) (Fig. 5A) and an Rdlic1/lgtF/lic2A strain
with the lpsA gene from strain R2846 that has a HepIII-1,2-Gal
epitope (Fig. 5B), and lpsA gene replacement was confirmed by
sequencing (see Fig. S4B). A change from glucose to galactose
attached to HepIII decreased IgM binding (Fig. 5C) but not IgG
binding (see Fig. S2H), as measured by flow cytometry andWest-
ern blot analysis (Fig. 5D). More importantly, neutrophil-
mediated killing of the Rdlic1/lgtF/lic2A mutant was signifi-
cantly decreased with incorporation of galactose onHepIII for the
Rdlic1/lgtF/lic2A R2846_lpsA mutant (Fig. 5E).
Invasive NTHi isolates incorporate galactose onto HepIII
more frequently. The presence of Thr at position 151 in the LpsA
protein results in specificity for galactose, whereas the presence of
Cys, Ala, or Met results in the incorporation of glucose. From 82
recently published NTHi genomes (27), 13 publically available
NTHi genomes, and 10 additional clinical NTHi strains, 103
(98%) contained an lpsA gene, indicating that ~2% of NTHi
strains do not incorporate any oligosaccharides on HepIII. Clust-
alW2 alignment (http://www.ebi.ac.uk/Tools/msa/clustalw2/) of
the LpsA proteins showed the presence of Thr in 26/105 (25%),
Cys in 61/105 (58%), Met in 15/105 (14%), or Ala in 1/105 (1%)
(see Fig. S4A in the supplemental material) on position 151, pre-
dicting incorporation of glucose or galactose in 73%or 25%of the
strains, respectively.
Of theNTHi isolates, 22were carriage strains, 41were obtained
from patients with otitis media (OM), 25 were from patients with
COPD, and 17 were invasive isolates. The percentage of strains
predicted to incorporated galactose or no saccharide (no lpsA
gene) onto HepIII was 14% for carriage strains, whereas this was
29% and 24% for strains isolated from patients with OM or
COPD, respectively (Table 2). Incorporation of galactose or no
saccharide onto HepIII was predicted for 41% of the strains col-
FIG 4 Phase-variable incorporation of galactose on HepIII-1,2-Glc blocks
binding of IgM and neutrophil-mediated killing. (A) Predicted LOS structure
of Rd (25) with phase-variable LOS synthesis genes in gray. (B) Rd LOS mu-
tants were incubated for 15 min with 5% NHS at 37°C, and binding of IgM to
the bacterial surface was determined by flow cytometry. (C) RdLOS mutants
were incubated with 1% NHS with or without neutrophils, and survival was
determined after incubation at 37°C for 30min. (D) LOSwas isolated fromRd
LOS mutants, separated by Tris Tricine SDS-PAGE, and visualized by silver
staining, or IgM binding was detected by Western blot analysis. (E) Rdlic1/
lgtF mutants exposed to 1% NHS with neutrophils for three rounds were
incubated for 15minwith 5%NHSat 37°C, and binding of IgM to the bacterial
surface was determined by flow cytometry. (F) Rdlic1/lgtF mutants exposed
to 1% NHS with neutrophils were incubated with 1% NHS with or without
neutrophils for three rounds, and survival was determined after incubation at
37°C for 30 min. (G) Rdlic1/lgtF/lic2A mutants exposed to 1% NHS with
neutrophils were incubated with 1% NHS with or without neutrophils for
three rounds, and survival was determined after incubation at 37°C for 30min.
Statistical significance was determined with a one-way analysis of variance and
the Tukey post hoc test. **, P 0.01; ***, P 0.001.
FIG 5 Binding of IgM is specific for an epitope that includes HepIII-1,2-
Glc, but not HepIII-1,2-Gal. (A) Predicted LOS structures of Rdlic1/lgtF/
lic2Aand (B) Rdlic1/lgtF/lic2A with lpsA gene from R2846. (C) Rdlic1/lgtF/
lic2A and Rdlic1/lgtF/lic2A R2846_lpsA mutants were incubated for 15 min
with 5% NHS at 37°C and binding of IgM to the bacterial surface was deter-
mined by flow cytometry. (D) LOS was isolated from Rdlic1/lgtF/lic2A and
Rdlic1/lgtF/lic2A R2846_lpsA mutants, separated by Tris-Tricine SDS-
PAGE, and visualized by silver staining or IgM binding was detected byWest-
ern blotting. (H) Rdlic1/lgtF/lic2A and Rdlic1/lgtF/lic2A R2846_lpsA mu-
tants were incubated with 1% NHS with or without neutrophils, and survival
was determined after incubation at 37°C for 30min. Statistical significancewas
determined using an unpaired Student t test. **, P 0.01; ***, P 0.001.
LOS Structure Prevents Neutrophil Phagocytosis
July/August 2014 Volume 5 Issue 4 e01478-14 ® mbio.asm.org 5
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
lected from patients with invasive disease (Table 2), which was
~3-fold more frequent than for carriage strains, indicating a rela-
tionship between incorporation of galactose or no saccharide onto
HepIII and the ability to cause invasive disease (Pearson chi-
square, 3.815; P 0.05). Collectively, these data support a role for
incorporation of galactose or no saccharide onto HepIII, thereby
preventing binding of IgM, which increases resistance to
neutrophil-mediated killing, although the presence and activity of
other glycosyltransferases such as lic2A, as shown in Fig. 4, also
contribute to the overall resistance phenotype.
DISCUSSION
In this study, we used Tn-seq to identify genes important for sur-
vival in the presence of pooled NHS with or without freshly iso-
lated human neutrophils. Multiple genes involved in LOS biosyn-
thesis were identified (Table 1), including the rfaD, rfaE, rfaF, and
waaQ genes, important for synthesis of the LOS inner core (28,
29). The rfaD gene mutant showed decreased virulence in a chin-
chilla model for OM (30) and increased killing by neutrophil ex-
tracellular traps (NETs) (11), emphasizing a critical role for the
LOS inner core in virulence of NTHi; however, the mechanisms
remained unexplored.
Multiple genes involved in synthesis of the variable LOS outer
core, including galE, galU, lic2A, and lgtC, were shown in ourwork
to be important in resisting killing by human neutrophils. Many
of these genes have previously been shown to contribute to resis-
tance to complement-mediated killing in the absence of neutro-
phils. Erwin et al., for example, described an important role for
lgtC in resistance to complement-mediated killing of strain R2866
(31), and each of these genes has been identified in recently pub-
lished transposonmutagenesis screens for genes involved in resis-
tance to the complement-dependent bactericidal effect of serum
(15, 32). The activation of complement on the bacterial surface
has both direct antimicrobial activity (formation of the mem-
brane attack complex) and indirect effects (opsonization).
Throughout our study, we have compared NHS containing active
complement with and without neutrophils, controlling for the
effect of complement alone and allowing us to focus on the addi-
tional contribution of neutrophils to NTHi killing.
Truncations of the R2866 LOS outer core resulted in increased
binding of IgM from pooled NHS. Even though detectable levels
of IgG binding were observed for NTHi with or without an intact
LOS outer core, increased binding of IgM was required to initiate
sufficient complement activation to promote neutrophil-
mediated uptake and killing. In contrast, the amount of comple-
ment deposition resulting from IgG binding did not appear to be
as effective at opsonizing the bacteria.
The contribution of IgM binding to the bacterial surface of
NTHi to efficient complement-mediated killing has been demon-
strated in various studies.We have previously shown that the level
of IgM binding correlated with complement-mediated killing for
NTHi strains collected from children with OM (15) and
complement-resistant NTHi isolates from patients with COPD
showed decreased IgM binding (32). Decreased binding of IgM to
complement-resistant isolates is likely to be multifactorial, be-
cause changes in the LOS, as well as exclusion of phospholipids
from the outer leaflet of the bacterial membrane, decreased IgM
binding and increased resistance to complement-mediated killing
(15, 32). Therefore, it appears that IgM recognition of NTHi plays
an important role in controlling infections with NTHi. This is
corroborated by clinical data from patients with hyper-IgM syn-
drome, who have a significantly lower risk of NTHi carriage than
children with panhypogammaglobulinemia, suggesting that IgM
antibodies, even in the absence of IgG or IgA, are protective and
contribute to the prevention of respiratory tract colonization and
infection (33).
Most vaccine studies for NTHi are focused on the use of im-
munogenic membrane-exposed proteins (34). However, anti-
genic variation and the absence of certain proteins in selected
NTHi isolates make it difficult to formulate a broadly protective
protein-based vaccine. Therefore, LOS might be an interesting
alternative, and this concept is supported by a vaccination study
with protein-conjugated LOS (35). Although the LOS of NTHi is
heterogeneous as well, immunization against specific LOS
epitopes masking immune-dominant structures might be an in-
teresting alternative, and several studies demonstrate the potential
of opsonizing LOS antibodies in opsonophagocytosis and protec-
tion inmousemodels. Mousemonoclonal antibodies recognizing
NTHi LOS after intraperitoneal immunization were shown to be
mainly IgM, and selected clones conferred bactericidal activity
and increased phagocytosis by human neutrophils (36). A mouse
immunization study with M. catarrhalis was shown to induce
cross-reactive IgM recognizing H. influenzae LOS, which in-
creased bactericidal activity in the presence of complement, dem-
onstrating that antibodies to single LOS epitopes could be protec-
tive (37).
We identified an important role for binding of IgM to LOS in
neutrophil-mediated killing. In order to determine the exact
epitope recognized by IgM,we generated a series ofmutant strains
that either had truncated oligosaccharide extensions or a complete
absence of oligosaccharides on HepI or HepIII. Although we have
not confirmed the LOS structures by mass spectrometry, altered
size as confirmed by Tris-Tricine gel electrophoresis and consis-
tent results for strains Rd, R2846 (data not shown), and R2866
present strong evidence that IgM from human serum recognizes
an epitope that contains HepIII-1,2-Glc but not HepIII-1,2-
Gal. Both galactose and glucose can be attached toHepIII in a1,2
or 1,3 linkage (26), but we have not addressed whether the link-
age has effect on binding of IgM.
AlthoughNTHi can incorporate a galactose onHepIII, thereby
increasing its resistance to neutrophil-mediated killing, in 73% of
NTHi strains incorporation of a glucose at this site is predicted
(Table 2). Therefore, it is tempting to speculate that the presence
of glucose on the HepIII might have advantages for NTHi under
specific conditions, like colonization of the upper respiratory
tract. Such apparent discrepancy is also found for incorporation
of PCho into the LOS structure. Although PCho is recognized by
C-reactive protein (CRP) and germ line-encoded IgM (21, 22),
thereby activating the classical complement pathway, the presence
of PCho contributes in colonization in animal models (17) and in
TABLE 2 Predicted distribution of glucose or galactose (Gal)
incorporation with HepIII by LpsA in 105 clinical NTHi isolates
Incorporation
No. (%) of isolates
TotalCarriage Otitis media COPD Invasive
Glc 19 (86.4) 29 (70.7) 19 (76.0) 10 (58.8) 77
Gal or no saccharide 3 (13.6) 12 (29.3) 6 (24.0) 7 (41.2) 28
Total 22 41 25 17 105
Langereis and Weiser
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a human colonizationmodel (38). Similar factors might be select-
ing for incorporation of glucose onto HepIII, but to our knowl-
edge this not been investigated.
Whereas incorporation of a galactose on HepIII is considered
to be a terminal moiety, glucose onHepIII can be substituted with
galactose depending on lic2A gene activity (19), which is con-
trolled by phase variation, a mechanism that switches translation
of genes on or off (39). Phase-variable on-off translation of genes
is a stochastic process dependent on slipped-strand mispairing of
tandem repeats present in the gene, which occurs with a high
frequency (102 to 103 times per generation) and leads to
switching the coding region in or out of frame. We showed that
selection for lic2A phase-on variants incorporating oligosaccha-
rides onto HepIII-1,2-Glc blocked binding of IgM, which pre-
vented neutrophil-mediated killing. These experiments are in ac-
cordance with experiments performed by Clark et al., where serial
exposure to NHS selected for lic2A phase-on variants and in-
creased complement resistance through decreased binding of IgG
(40). Since this is a phase-variable process, it raises the question of
the advantage forNTHi in switching between these twoLOS types.
As for PCho, oligosaccharide extensions on HepIII-1,2-Glc
might be an advantage or disadvantage for NTHi depending on
the location where it resides in the human host. Shielding of con-
served immune-dominant epitopes withmore-variable structures
has been observed not only forNTHi but also for other pathogens,
such as S. pneumoniae. For instance, pneumococcal surface pro-
teinA (PspA) binds to PCho and thereby blocks binding of CRP to
the bacterial surface, preventing C3 deposition (41).
Because IgM recognizing an epitope containing HepIII-1,2-
Glc was not present in cord blood plasma, we concluded that it is
not germ line encoded but is acquired in human serum from pre-
vious exposure. In contrast, we were unable to identify significant
levels of IgG recognizing this epitope. There is evidence that a large
proportion of memory B cells do not class switch but give rise to a
population called IgM CD27 memory B cells producing
antigen-specific IgM. This population ofmemory B cells accumu-
lates somatic mutations, although to a lower extent than IgG-
producing B cells, but does not class switch (42, 43), and we pro-
pose that IgM recognizing an epitope that includes HepIII-1,2-
Glc is produced by this type ofmemory B cell. Although the origin
and function of IgM CD27 memory B cells are under debate
(44), they appear to be an important part of the adaptive immune
response to various pathogens. The percentages of IgM CD27
memory B cells in the peripheral blood of children are low, in-
crease to almost 20% in adults, and decline in the elderly (45),
which corresponds with susceptibility to bacterial infections in
children and the elderly. An important protective role for IgM
CD27memory B cells was shown in patients with common vari-
able immunodeficiency (CVID) or splenectomized or asplenic pa-
tients, where the presence of anticapsular IgM CD27memory
B cells protected against bacterial pneumonia (46, 47). In addi-
tion, transient predisposition to infections caused by S. pneu-
moniae in very young children (2 years) was associated with the
lack of IgM CD27memory B cells and antipneumococcal cap-
sular IgM (47). Altogether, IgM appears to play an important role
in the adaptive immune response to pathogens, and exposing the
immune system through vaccination might increase the ability of
neutrophils to clear NTHi infections.
In conclusion, we have shown that IgM binding to the NTHi
LOS facilitates efficient neutrophil-mediated killing of NTHi, but
this pathogen has developed at least three mechanisms that pre-
vent binding of IgM to HepIII-1,2-Glc: (i) oligosaccharide ex-
tensions of HepI and possibly other heptose residues, (ii) phase-
variable incorporation of galactose onto HepIII-1,2-Glc, and
(iii) incorporation of galactose onto HepIII. Our findings suggest
that strategies to increase binding of IgM might enhance op-
sonization and phagocytic activity of human neutrophils and
thereby limit infections by NTHi.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Strains used in this study are
listed in Table S1 in the supplemental material (53–58). Bacteria were
grown with shaking at 37°C in brain heart infusion (BHI) broth (Becton,
Dickinson) supplemented with 2% Fildes enrichment (Thermo Scien-
tific) and 2 g/ml -NAD (Sigma-Aldrich) (sBHI). Viable bacterial
counts were determined by plating serial dilutions in phosphate-buffered
saline (PBS) on sBHI agar plates grown at 37°C with 5% CO2. Optical
density was measured at 620 nm. For mutant library and gene mutants,
100 g/ml spectinomycin (Calbiochem), 20 g/ml kanamycin (Fisher
Bioreagents), or 12.5 g/ml tetracycline (Sigma-Aldrich) was used.
Human neutrophils, normal human serum, and human nasal air-
way surface fluid.Bloodwas drawn fromhealthy adult donors in sodium-
heparin anticoagulation tubes (BD Vacutainer) and isolated using Ficoll-
Paque (GE Healthcare) as described previously (48). Before use,
neutrophils were taken up in Hanks’ buffered salt solution (HBSS) with-
out phenol red containingCa2 andMg2plus 0.1%gelatin to the desired
concentration. All experiments were performed with the same batch of
pooled normal human serum (NHS) containing opsonizing antibodies
and active complement obtained from GTI Diagnostics (catalogue no.
PHS-N100). For IgM depletion, 2 ml of 20% NHS in PBS was incubated
with 200 l of PBS-washed Sepharose beads coupled to anti-human IgM
antibody (Sigma). After 2 h of incubation while shaking at 4°C, Sepharose
beads were removed by centrifugation, and sera were diluted to 10%with
PBS and immediately stored at80°C. Donor-specificNHSwas obtained
from healthy adult volunteers, using serum tubes (BD Vacutainer), cen-
trifuged, and stored immediately at80°C. Human nasal airway surface
fluid was obtained from a healthy adult volunteer as described previously
(49).
Identifying NTHi genes essential for survival with NHS and human
neutrophils. Genomic DNA from NTHi strain R2866 was isolated from
mid-log-phase cultures using the Qiagen Genomic-tip 20/G tips (Qia-
gen), following the manufacturer’s protocol. The NTHi R2866
marinerT7-MmeI transposon mutant library was generated as described
previously for NTHi 86-028NP (50).
The NTHI R2866 marinerT7-MmeI transposon mutant library was
diluted to 2 106 CFU/ml in HEPES-buffered RPMI containing 1g/ml
hemin and 2 g/ml -NAD and incubated for 2 h in the presence of 10%
normal human serum (control) or 10% normal human serum with 2 
107 neutrophils/ml (multiplicity of infection [MOI], 0.1) in quadruplicate
at 37°C (end volume, 1 ml). After challenge, neutrophils were lysed by
adding 100 l 10% saponin in PBS and incubated for 10 min at room
temperature. Subsequently, 4 ml sBHI was added, and the mutant library
was grown to an optical density at 620 nm (OD620) of ~0.2 (~4 h), and
chromosomal DNA was isolated for Tn-seq analysis. Generation times
were confirmed by viable bacterial counts (see Fig. S1B in the supplemen-
tal material). Genomic DNA was isolated using a DNeasy Blood & Tissue
kit (Qiagen), following the manufacturer’s protocol. A readout of the
mutant library and data analysis were performed as described previously
(50). Analysis data can be found at http://bamics2.cmbi.ru.nl/websoftware
/essentials/essentials_run.php?sessionessentials%neutrophil.
Generation of NTHi-directed gene replacement mutants. Bacterial
genomic DNA was isolated using a DNeasy Blood & Tissue kit (Qiagen),
following the manufacturer’s protocol. Directed NTHi gene replacement
mutants were generated by allelic exchange of donor genomic DNA or by
allelic exchange of the target gene with an antibiotic resistance marker, as
LOS Structure Prevents Neutrophil Phagocytosis
July/August 2014 Volume 5 Issue 4 e01478-14 ® mbio.asm.org 7
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
described previously (50). Mutants were selected by plating on sBHI
plates containing 100 g/ml spectinomycin, 20 g/ml kanamycin, or
12.5 g/ml tetracycline and validated by PCR. All primers used in this
study are listed in Table S1 in the supplemental material.
lpsA gene replacement in Rdlic1/lgtF/lic2A. The R2846 lpsA gene
was PCR amplified using the primers NTHi_lpsA_F_uptake andNTHi_l-
psA_R_uptake (see Table S1 in the supplemental material), containing
uptake sequences for increased transformation efficiency. The PCR prod-
uct was purified using the QIAquick PCR purification kit (Qiagen), fol-
lowing the manufacturer’s protocol, and 5 g PCR product or water as a
control was incubated 1 hwith 500lM-IV competent (51) Rdlic1/lgtF/
lic2A bacteria. Five hundredmicroliters sBHI was added to enable growth
for 2 h at 37°C with shaking at 225 rpm. Cultures were washed with HBSS
without phenol red containing Ca2 and Mg2 plus 0.1% gelatin and
diluted to ~1 107 bacteria/ml. One hundred microliters culture (~1
106 bacteria) was incubatedwith 5%NHS for 30min, plated on sBHI, and
grown overnight at 37°C plus 5% CO2 to select for complement-resistant
transformants. Complement resistance assay was repeated with the sur-
viving bacteria to enrich the selection. Single colonies were picked for
growth and DNA isolation, and the lpsA gene was PCR amplified with the
primers NTHi_lpsA_F2 and NTHi_lpsA_R1 (see Table S1). Replacement
of the Rd lpsA gene (cysteine [C] at amino acid position 151) with the
R2846 lpsA gene (threonine [T] at amino acid position 151) was con-
firmed by sequencing (see Fig. S4B).
Flow cytometric analysis. Bacteria were grown to anOD620 of ~0.6 in
sBHI medium, washed with HBSS without phenol red containing Ca2
and Mg2, and diluted to an OD620 of 0.2. Surface opsonization with
serumwas performed by incubating 50l bacteria with 50l 10% pooled
NHS, 10% cord blood plasma, or 1:250-diluted TEPC-15 in HBSS with-
out phenol red containing Ca2 andMg2 or human nasal airway surface
fluid for 15 min at 37°C with 5% CO2. Opsonized bacteria were fixed for
20 min with 2% paraformaldehyde, washed, and incubated with 1:500-
diluted fluorescein isothiocyanate (FITC)-labeled polyclonal goat anti-
human C3 (MP Biomedicals), 1:100-diluted FITC-labeled Fc-specific
goat anti-human IgG, 1:50-diluted FITC-labeled -chain-specific goat
anti-human IgM (Sigma-Aldrich), or 1:100-diluted FITC-labeled
-chain-specific goat anti-mouse IgA for TEPC-15 in HBSS without phe-
nol red containing Ca2 and Mg2 plus 5% FCS for 30 min at 4°C. Bac-
teria were washed and resuspended in PBS for flow cytometry. Binding
was detected by flow cytometry using a FACS LSR II instrument (BD
Biosciences). Data were analyzed using the software program FlowJo ver-
sion 7.6.3. Measurement of geometric mean fluorescence intensity (MFI)
was depicted in arbitrary units (AU).
Neutrophil killing assay. Bacteria were grown to an OD620 of ~0.6 in
sBHI, washed with HBSS without phenol red containing Ca2 andMg2,
and diluted to 2  105 CFU/ml in HBSS without phenol red containing
Ca2 and Mg2 plus 0.1% gelatin. Neutrophils were resuspended in
HBSSwithout phenol red containing Ca2 andMg2 plus 0.1% gelatin to
4  106/ml (ratio, 1:20), 1  107/ml (ratio, 1:50), or 2  107/ml (ratio,
1:100). For inhibition experiments, neutrophils (2 107/ml) were prein-
cubated with 20Mcytochalasin D (Sigma), 1 protease inhibitor cock-
tail (Calbiochem), 1 mMmyeloperoxidase (MPO) inhibitor, 10ME-64
(Sigma), 500 M AEBSF (Calbiochem), or 200 M DFP (Sigma) for
15min at 37°Cwith 5%CO2.Next, 10l heat-inactivatedNHS (HI-NHS)
orNHSof the desired concentration, 45l bacteria, and 45l neutrophils
were mixed and incubated for 30 min at 37°C with 5% CO2. CFU counts
were determined by plating 10-fold dilutions on sBHI plates and incu-
bated overnight at 37°C with 5% CO2. For the Rdlic1/lgtF and Rdlic1/
lgtF/lic2A mutants, surviving colonies from round 1 were subsequently
incubated with 1% NHS with or without neutrophils, and survival was
determined after a 30-min incubation (round 2), which was repeated for
another round (round 3).
LOS analysis by Tris-Tricine SDS-PAGE. LOS was isolated as de-
scribed previously (52). LOS samples were separated on a Tris-Tricine
SDS-PAGE gel with a Protean II xi cell electrophoresis system (Bio-Rad)
and visualized by silver staining or transferred to a polyvinylidene diflu-
oride (PVDF)membrane forWestern blotting. Membranes were blocked
with 5% bovine serum albumin (BSA) in PBS for 1 h, incubated for 2 h
with 5%NHS in PBS, washed 5 times for 5 min (each) with Tris-buffered
saline plus 0.05% Tween 20, and incubated with 1:3,000-diluted alkaline
phosphatase (AP)-labeled goat-anti-human IgM -chain (Sigma-
Aldrich). Binding was detected with NBT (4-nitroblue tetrazolium
chloride)-BCIP (5-bromo-4-chloro-3-indolyl phosphate) (Roche), fol-
lowing the manufacturer’s instructions.
Sequence analysis of lic2Aphase-variable region.GenomicDNAwas
isolated from 1 ml culture (original and post-exposure to NHS and neu-
trophils) for sequence analysis. Primers lic2F and lic2R (see Table S1 in the
supplemental material) were used to amplify the lic2A gene, which in-
cluded the tetranucleotide repeat. The number of repeats was counted
from each sequence and used to determine reading frame status as in
frame (ON) or out of frame (OFF) (see Fig. S3).
Statistical analysis. Statistical analyses were performed using Graph-
Pad Prism version 5 (GraphPad Software), where a P value of0.05 was
considered significant. The specific statistical tests that were used for the
various experiments are specified in the figure legends. The program SPSS
version 22 (IBM) was used to analyze the predicted galactose or glucose
incorporation with HepIII with a chi-square test.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.01478-14/-/DCSupplemental.
Figure S1, PDF file, 0.2 MB.
Figure S2, PDF file, 0.3 MB.
Figure S3, PDF file, 0.2 MB.
Figure S4, PDF file, 1.1 MB.
Table S1, PDF file, 0.1 MB.
ACKNOWLEDGMENTS
This work is supported by a Dutch Lung Foundation long-term fellow-
ship, grant number 3.2.12.126FE (to J.D.L.), and grants from the U.S.
Public Health Service, AI078538 and AI044231 (to J.N.W.).
REFERENCES
1. Heath PT. 1998. Haemophilus influenzae type b conjugate vaccines: a
review of efficacy data. Pediatr. Infect. Dis. J. 17:S117–S122. http://
dx.doi.org/10.1097/00006454-199809001-00005.
2. Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay
ME, European Union Invasive Bacterial Infection Surveillance. 2010.
InvasiveHaemophilus influenzae disease, Europe, 1996–2006. Emerg. In-
fect. Dis. 16:455–463. http://dx.doi.org/10.3201/eid1603.090290.
3. Stol K, Verhaegh SJ, Graamans K, Engel JA, Sturm PD, Melchers WJ,
Meis JF, Warris A, Hays JP, Hermans PW. 2013. Microbial profiling
does not differentiate between childhood recurrent acute otitis media and
chronic otitis media with effusion. Int. J. Pediatr. Otorhinolaryngol. 77:
488–493. http://dx.doi.org/10.1016/j.ijporl.2012.12.016.
4. Brook I. 2011. Microbiology of sinusitis. Proc. Am. Thorac. Soc.
8:90–100. http://dx.doi.org/10.1513/pats.201006-038RN.
5. Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant BJ, Murphy TF.
2007. Airway bacterial concentrations and exacerbations of chronic ob-
structive pulmonary disease. Am. J. Respir. Crit. Care Med. 176:356–361.
http://dx.doi.org/10.1164/rccm.200703-417OC.
6. Hallström T, Resman F, Ristovski M, Riesbeck K. 2010. Binding of
complement regulators to invasive nontypeable Haemophilus influenzae
isolates is not increased compared to nasopharyngeal isolates, but serum
resistance is linked to disease severity. J. Clin. Microbiol. 48:921–927.
http://dx.doi.org/10.1128/JCM.01654-09.
7. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. 2000. Associa-
tion between airway bacterial load andmarkers of airway inflammation in
patients with stable chronic bronchitis. Am. J. Med. 109:288–295. http://
dx.doi.org/10.1016/S0002-9343(00)00507-6.
8. Kolaczkowska E, Kubes P. 2013. Neutrophil recruitment and function in
health and inflammation. Nat. Rev. Immunol. 13:159–175. http://
dx.doi.org/10.1038/nri3399.
9. Lysenko ES, Ratner AJ, Nelson AL, Weiser JN. 2005. The role of innate
Langereis and Weiser
8 ® mbio.asm.org July/August 2014 Volume 5 Issue 4 e01478-14
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
immune responses in the outcome of interspecies competition for coloni-
zation of mucosal surfaces. PLoS Pathog. 1:e1. http://dx.doi.org/10.1371/
journal.ppat.0010001.
10. Juneau RA, Pang B, Weimer KE, Armbruster CE, Swords WE. 2011.
Nontypeable Haemophilus influenzae initiates formation of neutrophil
extracellular traps. Infect. Immun. 79:431– 438. http://dx.doi.org/
10.1128/IAI.00660-10.
11. Hong W, Juneau RA, Pang B, Swords WE. 2009. Survival of bacterial
biofilms within neutrophil extracellular traps promotes nontypeableHae-
mophilus influenzae persistence in the chinchillamodel for otitismedia. J.
Innate Immun. 1:215–224. http://dx.doi.org/10.1159/000205937.
12. Langereis JD. 2013. Neutrophil integrin affinity regulation in adhesion,
migration, and bacterial clearance. Cell Adh. Migr. 7:476–481. http://
dx.doi.org/10.4161/cam.27293.
13. Hallström T, Jarva H, Riesbeck K, Blom AM. 2007. Interaction with
C4b-binding protein contributes to nontypeable Haemophilus influenzae
serum resistance. J. Immunol. 178:6359–6366. http://dx.doi.org/10.4049/
jimmunol.178.10.6359.
14. Hallström T, Zipfel PF, Blom AM, Lauer N, Forsgren A, Riesbeck K.
2008. Haemophilus influenzae interacts with the human complement in-
hibitor factor H. J. Immunol. 181:537–545. http://dx.doi.org/10.4049/
jimmunol.181.1.537.
15. Langereis JD, Stol K, Schweda EK, Twelkmeyer B, Bootsma HJ, de Vries
SP, Burghout P, Diavatopoulos DA, Hermans PW. 2012. Modified
lipooligosaccharide structure protects nontypeableHaemophilus influen-
zae from IgM-mediated complement killing in experimental otitis media.
mBio 3(4):e00079-00012. http://dx.doi.org/10.1128/mBio.00079-12.
16. Ho DK, Ram S, Nelson KL, Bonthuis PJ, Smith AL. 2007. lgtC expres-
sion modulates resistance to C4b deposition on an invasive nontypeable
Haemophilus influenzae. J. Immunol. 178:1002–1012. http://dx.doi.org/
10.4049/jimmunol.178.2.1002.
17. Clark SE, Snow J, Li J, Zola TA, Weiser JN. 2012. Phosphorylcholine
allows for evasion of bactericidal antibody by Haemophilus influenzae.
PLoS Pathog . 8 :e1002521 . ht tp : / /dx .doi .org/10 .1371/
journal.ppat.1002521.
18. Virji M, Weiser JN, Lindberg AA, Moxon ER. 1990. Antigenic similar-
ities in lipopolysaccharides of Haemophilus and Neisseria and expression
of a digalactoside structure also present on human cells. Microb. Pathog.
9:441–450. http://dx.doi.org/10.1016/0882-4010(90)90062-U.
19. Schweda EK, Twelkmeyer B, Li J. 2008. Profiling structural elements of
short-chain lipopolysaccharide of non-typeable Haemophilus influenzae.
Innate Immun. 14 :199 –211 . ht tp : / /dx .doi .org/10 .1177/
1753425908095958.
20. Holden HM, Rayment I, Thoden JB. 2003. Structure and function of
enzymes of the Leloir pathway for galactose metabolism. J. Biol. Chem.
278:43885–43888. http://dx.doi.org/10.1074/jbc.R300025200.
21. Ehrenstein MR, Notley CA. 2010. The importance of natural IgM: scav-
enger, protector and regulator. Nat. Rev. Immunol. 10:778–786. http://
dx.doi.org/10.1038/nri2849.
22. Weiser JN, Pan N, McGowan KL, Musher D, Martin A, Richards J.
1998. Phosphorylcholine on the lipopolysaccharide of Haemophilus in-
fluenzae contributes to persistence in the respiratory tract and sensitivity
to serum killing mediated by C-reactive protein. J. Exp. Med. 187:
631–640. http://dx.doi.org/10.1084/jem.187.4.631.
23. Engskog M. 2010. Structural and genetic characterization of lipopolysac-
charides extracted from disease causing non-typeable Haemophilus influ-
enzae strains. Doctoral thesis. Karolinska Institutet, Stockholm, Sweden.
http://hdl.handle.net/10616/39835.
24. Weiser JN, Maskell DJ, Butler PD, Lindberg AA, Moxon ER. 1990.
Characterization of repetitive sequences controlling phase variation of
Haemophilus influenzae lipopolysaccharide. J. Bacteriol. 172:3304–3309.
25. Hood DW, Cox AD, Wakarchuk WW, Schur M, Schweda EK, Walsh
SL, Deadman ME, Martin A, Moxon ER, Richards JC. 2001. Genetic
basis for expression of the major globotetraose-containing lipopolysac-
charide fromH. influenzae strain Rd (RM118). Glycobiology 11:957–967.
http://dx.doi.org/10.1093/glycob/11.11.957.
26. Deadman ME, Lundström SL, Schweda EK, Moxon ER, Hood DW.
2006. Specific amino acids of the glycosyltransferase LpsA direct the addi-
tion of glucose or galactose to the terminal inner core heptose of Haemo-
philus influenzae lipopolysaccharide via alternative linkages. J. Biol.
Chem. 281:29455–29467. http://dx.doi.org/10.1074/jbc.M604908200.
27. De Chiara M, Hood D, Muzzi A, Pickard DJ, Perkins T, Pizza M,
Dougan G, Rappuoli R, Moxon ER, Soriani M, Donati C. 2014. Genome
sequencing of disease and carriage isolates of nontypeable Haemophilus
influenzae identifies discrete population structure. Proc. Natl. Acad. Sci.
U. S. A. 111:5439–5444. http://dx.doi.org/10.1073/pnas.1403353111.
28. Nichols WA, Gibson BW, Melaugh W, Lee NG, Sunshine M, Apicella
MA. 1997. Identification of the ADP-L-glycero-D-manno-heptose-6-
epimerase (rfaD) and heptosyltransferase II (rfaF) biosynthesis genes
from nontypeable Haemophilus influenzae 2019. Infect. Immun. 65:
1377–1386.
29. Lee NG, Sunshine MG, Apicella MA. 1995. Molecular cloning and char-
acterization of the nontypeable Haemophilus influenzae 2019 rfaE gene
required for lipopolysaccharide biosynthesis. Infect. Immun. 63:818–824.
30. DeMaria TF, Apicella MA, Nichols WA, Leake ER. 1997. Evaluation of
the virulence of nontypeable Haemophilus influenzae lipooligosaccharide
htrB and rfaD mutants in the chinchilla model of otitis media. Infect.
Immun. 65:4431–4435.
31. Erwin AL, Allen S, Ho DK, Bonthuis PJ, Jarisch J, Nelson KL, Tsao DL,
Unrath WC, Watson ME, Jr, Gibson BW, Apicella MA, Smith AL. 2006.
Role of lgtC in resistance of nontypeable Haemophilus influenzae strain
R2866 to human serum. Infect. Immun. 74:6226–6235. http://dx.doi.org/
10.1128/IAI.00722-06.
32. Nakamura S, Shchepetov M, Dalia AB, Clark SE, Murphy TF, Sethi S,
Gilsdorf JR, Smith AL, Weiser JN. 2011. Molecular basis of increased
serum resistance among pulmonary isolates of non-typeable Haemophi-
lus influenzae. PLoS Pathog. 7:e1001247. http://dx.doi.org/10.1371/
journal.ppat.1001247.
33. Micol R, Kayal S, Mahlaoui N, Beauté J, Brosselin P, Dudoit Y, Obenga
G, Barlogis V, Aladjidi N, Kebaili K, Thomas C, Dulieu F, Monpoux F,
Nové-Josserand R, Pellier I, Lambotte O, Salmon A, Masseau A,
Galanaud P, Oksenhendler E, Tabone MD, Teira P, Coignard-Biehler
H, Lanternier F, Join-Lambert O, Mouillot G, Theodorou I, Lecron JC,
Alyanakian MA, Picard C, Blanche S, Hermine O, Suarez F, Debré M,
Lecuit M, Lortholary O, Durandy A, Fischer A. 2012. Protective effect of
IgM against colonization of the respiratory tract by nontypeable Haemo-
philus influenzae in patients with hypogammaglobulinemia. J. Allergy
Cl in . Immunol . 129 :770 –777 . ht tp : / /dx .doi .org/10 .1016/
j.jaci.2011.09.047.
34. Poolman JT, Bakaletz L, Cripps A, Denoel PA, Forsgren A, Kyd J, Lobet
Y. 2000. Developing a nontypeable Haemophilus influenzae (NTHi) vac-
cine. Vaccine 19(Suppl 1):S108–S115. http://dx.doi.org/10.1016/S0264-
410X(00)00288-7.
35. Hong W, Peng D, Rivera M, Gu XX. 2010. Protection against nontype-
able Haemophilus influenzae challenges by mucosal vaccination with a
detoxified lipooligosaccharide conjugate in two chinchilla models. Mi-
crobes Infect. 12:11–18. http://dx.doi.org/10.1016/j.micinf.2009.09.006.
36. Ueyama T, Gu XX, Tsai CM, Karpas AB, Lim DJ. 1999. Identification of
common lipooligosaccharide types in isolates from patients with otitis
media bymonoclonal antibodies against nontypeableHaemophilus influ-
enzae 9274. Clin. Diagn. Lab. Immunol. 6:96–100.
37. Gergova RT, Iankov ID, Haralambieva IH, Mitov IG. 2007. Bactericidal
monoclonal antibody against Moraxella catarrhalis lipooligosaccharide
cross-reacts with Haemophilus spp. Curr. Microbiol. 54:85–90. http://
dx.doi.org/10.1007/s00284-005-0463-6.
38. Poole J, Foster E, Chaloner K, Hunt J, Jennings MP, Bair T, Knudtson
K, Christensen E, Munson RS, Jr, Winokur PL, Apicella MA. 2013.
Analysis of nontypeable Haemophilus influenzae phase-variable genes
during experimental human nasopharyngeal colonization. J. Infect. Dis.
208:720–727. http://dx.doi.org/10.1093/infdis/jit240.
39. Weiser JN, Love JM, Moxon ER. 1989. The molecular mechanism of
phase variation of H. influenzae lipopolysaccharide. Cell 59:657–665.
http://dx.doi.org/10.1016/0092-8674(89)90011-1.
40. Clark SE, Eichelberger KR, Weiser JN. 2013. Evasion of killing by human
antibody and complement through multiple variations in the surface oli-
gosaccharide of Haemophilus influenzae. Mol. Microbiol. 88:603–618.
http://dx.doi.org/10.1111/mmi.12214.
41. Mukerji R, Mirza S, Roche AM, Widener RW, Croney CM, Rhee DK,
Weiser JN, Szalai AJ, Briles DE. 2012. Pneumococcal surface protein A
inhibits complement deposition on the pneumococcal surface by compet-
ing with the binding of C-reactive protein to cell-surface phosphocholine.
J . Immunol . 189 :5327–5335 . ht tp : / /dx .doi .org/10 .4049/
jimmunol.1201967.
42. Klein U, Rajewsky K, Küppers R. 1998. Human immunoglobulin
(Ig)MIgD peripheral blood B cells expressing the CD27 cell surface
antigen carry somaticallymutated variable region genes: CD27 as a general
LOS Structure Prevents Neutrophil Phagocytosis
July/August 2014 Volume 5 Issue 4 e01478-14 ® mbio.asm.org 9
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
marker for somatically mutated (memory) B cells. J. Exp. Med. 188:
1679–1689. http://dx.doi.org/10.1084/jem.188.9.1679.
43. Klein U, Küppers R, Rajewsky K. 1997. Evidence for a large compart-
ment of IgM-expressingmemory B cells in humans. Blood 89:1288–1298.
44. Tangye SG, GoodKL. 2007. Human IgMCD27 B cells: memory B cells
or “memory” B cells? J. Immunol. 179:13–19. http://dx.doi.org/10.4049/
jimmunol.179.1.13.
45. Shi Y, Agematsu K, Ochs HD, Sugane K. 2003. Functional analysis of
humanmemory B-cell subpopulations: IgDCD27 B cells are crucial in
secondary immune response by producing high affinity IgM. Clin. Immu-
nol. 108:128–137. http://dx.doi.org/10.1016/S1521-6616(03)00092-5.
46. Carsetti R, Rosado MM, Donnanno S, Guazzi V, Soresina A, Meini A,
Plebani A, Aiuti F, Quinti I. 2005. The loss of IgM memory B cells
correlates with clinical disease in common variable immunodeficiency. J.
Allergy Clin. Immunol. 115:412– 417. http://dx.doi.org/10.1016/
j.jaci.2004.10.048.
47. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O,
Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I, Carsetti
R. 2003. Human immunoglobulin M memory B cells controlling Strep-
tococcus pneumoniae infections are generated in the spleen. J. Exp. Med.
197:939–945. http://dx.doi.org/10.1084/jem.20022020.
48. Langereis JD, Franciosi L, Ulfman LH, Koenderman L. 2011. GM-CSF
and TNFmodulate protein expression of human neutrophils visualized
by fluorescence two-dimensional difference gel electrophoresis. Cytokine
56:422–429. http://dx.doi.org/10.1016/j.cyto.2011.06.025.
49. Gould JM, Weiser JN. 2001. Expression of C-reactive protein in the
human respiratory tract. Infect. Immun. 69:1747–1754. http://dx.doi.org/
10.1128/IAI.69.3.1747-1754.2001.
50. Langereis JD, Zomer A, Stunnenberg HG, Burghout P, Hermans PW.
2013. NontypeableHaemophilus influenzae carbonic anhydrase is impor-
tant for environmental and intracellular survival. J. Bacteriol. 195:
2737–2746. http://dx.doi.org/10.1128/JB.01870-12.
51. Herriott RM, Meyer EM, Vogt M. 1970. Defined nongrowth media for
stage II development of competence in Haemophilus influenzae. J. Bacte-
riol. 101:517–524.
52. Jones PA, Samuels NM, Phillips NJ, Munson RS, Jr, Bozue JA, Arse-
neau JA, Nichols WA, Zaleski A, Gibson BW, Apicella MA. 2002.
Haemophilus influenzae type b strain A2 has multiple sialyltransferases
involved in lipooligosaccharide sialylation. J. Biol. Chem. 277:
14598–14611. http://dx.doi.org/10.1074/jbc.M110986200.
53. Williams BJ, Morlin G, Valentine N, Smith AL. 2001. Serum resistance
in an invasive, nontypeable Haemophilus influenzae strain. Infect. Im-
mun. 69:695–705. http://dx.doi.org/10.1128/IAI.69.2.695-705.2001.
54. Hood DW, Deadman ME, Allen T, Masoud H, Martin A, Brisson JR,
Fleischmann R, Venter JC, Richards JC, Moxon ER. 1996. Use of the
complete genome sequence information of Haemophilus influenzae
strain Rd to investigate lipopolysaccharide biosynthesis. Mol. Microbiol.
22:951–965. http://dx.doi.org/10.1046/j.1365-2958.1996.01545.x.
55. Lysenko E, Richards JC, Cox AD, Stewart A, Martin A, Kapoor M,
Weiser JN. 2000. The position of phosphorylcholine on the lipopolysac-
charide of Haemophilus influenzae affects binding and sensitivity to
C-reactive protein-mediated killing. Mol. Microbiol. 35:234–245. http://
dx.doi.org/10.1046/j.1365-2958.2000.01707.x.
56. Puig C, Marti S, Hermans PW, de Jonge MI, Ardanuy C, Liñares J,
Langereis JD. 2014. Incorporation of phosphorylcholine into the lipooli-
gosaccharide of nontypeable Haemophilus influenzae does not correlate
with the level of biofilm formation in vitro. Infect. Immun. 82:1591–1599.
http://dx.doi.org/10.1128/IAI.01445-13.
57. de Vries SP, Burghout P, Langereis JD, Zomer A, Hermans PW,
Bootsma HJ. 2013. Genetic requirements for Moraxella catarrhalis
growth under iron-limiting conditions. Mol. Microbiol. 87:14–29. http://
dx.doi.org/10.1111/mmi.12081.
58. Weiser JN, Pan N. 1998. Adaptation of Haemophilus influenzae to ac-
quired and innate humoral immunity based on phase variation of lipo-
polysaccharide. Mol. Microbiol. 30:767–775. http://dx.doi.org/10.1046/
j.1365-2958.1998.01108.x.
Langereis and Weiser
10 ® mbio.asm.org July/August 2014 Volume 5 Issue 4 e01478-14
 
m
bio.asm
.org
 o
n
 O
ctober 14, 2015 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
